Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
The use of radiation therapy has become a staple in breast cancer treatment, with benefits seen in node-positive patients, those with locally advanced disease, and those with large-sized tumors.
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...
Liz O'Riordan felt immense guilt for how breast cancer affected her marriage and her sex drive - here's how she overcame it ...
Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
The mother of two expressed one of her biggest concerns after her cancer treatment—whether she has unknowingly increased the ...
Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...
Alaska has a low breast cancer screening rate. So, a few businesses offer evening parties with food and drink, where friends ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
With a focus on healthy living and information on advances in breast cancer treatment, Mayo Clinic is holding an educational event at Donna Marathon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback